Literature DB >> 29141225

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Clemens Krepler1, Katrin Sproesser1, Patricia Brafford1, Marilda Beqiri1, Bradley Garman2, Min Xiao1, Batool Shannan1, Andrea Watters1, Michela Perego1, Gao Zhang1, Adina Vultur1, Xiangfan Yin1, Qin Liu1, Ioannis N Anastopoulos2, Bradley Wubbenhorst2, Melissa A Wilson2, Wei Xu3, Giorgos Karakousis3, Michael Feldman3, Xiaowei Xu3, Ravi Amaravadi3, Tara C Gangadhar3, David E Elder3, Lauren E Haydu4, Jennifer A Wargo4, Michael A Davies4, Yiling Lu4, Gordon B Mills4, Dennie T Frederick5, Michal Barzily-Rokni5, Keith T Flaherty5, Dave S Hoon6, Michael Guarino7, Joseph J Bennett7, Randall W Ryan7, Nicholas J Petrelli7, Carol L Shields8, Mizue Terai9, Takami Sato9, Andrew E Aplin9, Alexander Roesch10, David Darr11, Steve Angus11, Rakesh Kumar12, Ensar Halilovic13, Giordano Caponigro13, Sebastien Jeay13, Jens Wuerthner13, Annette Walter14, Matthias Ocker14, Matthew B Boxer15, Lynn Schuchter3, Katherine L Nathanson2, Meenhard Herlyn16.   

Abstract

Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further advancements through pre-clinical in vivo modeling, we have established 459 patient-derived xenografts (PDX) and live tissue samples from 384 patients representing the full spectrum of clinical, therapeutic, mutational, and biological heterogeneity of melanoma. PDX have been characterized using targeted sequencing and protein arrays and are clinically annotated. This exhaustive live tissue resource includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-responders to immune checkpoint blockade, and 31 samples from brain metastasis. Uveal, mucosal, and acral subtypes are represented as well. We show examples of pre-clinical trials that highlight how the PDX collection can be used to develop and optimize precision therapies, biomarkers of response, and the targeting of rare genetic subgroups.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF inhibitor resistance; ERK inhibitor; MDM2 inhibitor; PI3K beta inhibitor; immune checkpoint blockade; in vivo models; melanoma; melanoma brain metastasis; patient-derived xenografts; targeted therapy

Mesh：

Year:  2017        PMID： 29141225      PMCID： PMC5726788          DOI： 10.1016/j.celrep.2017.10.021

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  55 in total

Review 1.  Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

Authors:  M F Sanmamed; C Chester; I Melero; H Kohrt
Journal:  Ann Oncol       Date:  2016-02-23       Impact factor: 32.976

2.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.

Authors:  Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

3.  Heterotransplantation of a human malignant tumour to "Nude" mice.

Authors:  J Rygaard; C O Povlsen
Journal:  Acta Pathol Microbiol Scand       Date:  1969

4.  Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).

Authors:  Andrea Forschner; Felizitas Eichner; Teresa Amaral; Ulrike Keim; Claus Garbe; Thomas Kurt Eigentler
Journal:  J Cancer Res Clin Oncol       Date:  2016-11-22       Impact factor: 4.553

5.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Authors:  Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo
Journal:  Cancer Discov       Date:  2016-06-14       Impact factor: 39.397

Review 6.  Targeting T Cell Co-receptors for Cancer Therapy.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.

Authors:  Amanda D Bucheit; Guo Chen; Alan Siroy; Michael Tetzlaff; Russell Broaddus; Denai Milton; Patricia Fox; Roland Bassett; Patrick Hwu; Jeffrey E Gershenwald; Alexander J Lazar; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-08-27       Impact factor: 12.531

8.  Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

Authors:  Mohammad Atefi; Erika von Euw; Narsis Attar; Charles Ng; Connie Chu; Deliang Guo; Ramin Nazarian; Bartosz Chmielowski; John A Glaspy; Begonya Comin-Anduix; Paul S Mischel; Roger S Lo; Antoni Ribas
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

9.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Authors:  Michael Krauthammer; Yong Kong; Antonella Bacchiocchi; Perry Evans; Natapol Pornputtapong; Cen Wu; Jamie P. McCusker; Shuangge Ma; Elaine Cheng; Robert Straub; Merdan Serin; Marcus Bosenberg; Stephan Ariyan; Deepak Narayan; Mario Sznol; Harriet M Kluger; Shrikant Mane; Joseph Schlessinger; Richard P Lifton; Ruth Halaban
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 41.307

10.  Recurrent inactivating RASA2 mutations in melanoma.

Authors:  Rand Arafeh; Nouar Qutob; Rafi Emmanuel; Alona Keren-Paz; Jason Madore; Abdel Elkahloun; James S Wilmott; Jared J Gartner; Antonella Di Pizio; Sabina Winograd-Katz; Sivasish Sindiri; Ron Rotkopf; Ken Dutton-Regester; Peter Johansson; Antonia L Pritchard; Nicola Waddell; Victoria K Hill; Jimmy C Lin; Yael Hevroni; Steven A Rosenberg; Javed Khan; Shifra Ben-Dor; Masha Y Niv; Igor Ulitsky; Graham J Mann; Richard A Scolyer; Nicholas K Hayward; Yardena Samuels
Journal:  Nat Genet       Date:  2015-10-26       Impact factor: 38.330
View more
  57 in total

Review 1.  Genomic evolution of cancer models: perils and opportunities.

Authors:  Uri Ben-David; Rameen Beroukhim; Todd R Golub
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

2.  Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.

Authors:  Keith M Giles; Brooke E Rosenbaum; Marlies Berger; Allison Izsak; Yang Li; Irineu Illa Bochaca; Eleazar Vega-Saenz de Miera; Jinhua Wang; Farbod Darvishian; Hua Zhong; Iman Osman
Journal:  J Invest Dermatol       Date:  2018-08-24       Impact factor: 8.551

3.  ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.

Authors:  Claudia Capparelli; Timothy J Purwin; Shea A Heilman; Inna Chervoneva; Peter A McCue; Adam C Berger; Michael A Davies; Jeffrey E Gershenwald; Clemens Krepler; Andrew E Aplin
Journal:  Cancer Res       Date:  2018-08-16       Impact factor: 12.701

4.  Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.

Authors:  Rachael A Vaubel; Shulan Tian; Dioval Remonde; Mark A Schroeder; Ann C Mladek; Gaspar J Kitange; Alissa Caron; Thomas M Kollmeyer; Rebecca Grove; Sen Peng; Brett L Carlson; Daniel J Ma; Gobinda Sarkar; Lisa Evers; Paul A Decker; Huihuang Yan; Harshil D Dhruv; Michael E Berens; Qianghu Wang; Bianca M Marin; Eric W Klee; Andrea Califano; Daniel H LaChance; Jeanette E Eckel-Passow; Roel G Verhaak; Erik P Sulman; Terry C Burns; Fredrick B Meyer; Brian P O'Neill; Nhan L Tran; Caterina Giannini; Robert B Jenkins; Ian F Parney; Jann N Sarkaria
Journal:  Clin Cancer Res       Date:  2019-12-18       Impact factor: 12.531

5.  BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.

Authors:  Cigdem Atay; Taekyoung Kwak; Sergio Lavilla-Alonso; Laxminarasimha Donthireddy; Allison Richards; Valerie Moberg; Shari Pilon-Thomas; Michael Schell; Jane L Messina; Vito W Rebecca; Min Xiao; Jiufeng Tan; Gao Zhang; Jeffrey S Weber; Meenhard Herlyn; Amod A Sarnaik; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2019-02-14       Impact factor: 12.531

6.  A Melanoma Patient-Derived Xenograft Model.

Authors:  Min Xiao; Vito W Rebecca; Meenhard Herlyn
Journal:  J Vis Exp       Date:  2019-05-20       Impact factor: 1.355

7.  Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.

Authors:  Bradley Garman; Ioannis N Anastopoulos; Clemens Krepler; Patricia Brafford; Katrin Sproesser; Yuchao Jiang; Bradley Wubbenhorst; Ravi Amaravadi; Joseph Bennett; Marilda Beqiri; David Elder; Keith T Flaherty; Dennie T Frederick; Tara C Gangadhar; Michael Guarino; David Hoon; Giorgos Karakousis; Qin Liu; Nandita Mitra; Nicholas J Petrelli; Lynn Schuchter; Batool Shannan; Carol L Shields; Jennifer Wargo; Brandon Wenz; Melissa A Wilson; Min Xiao; Wei Xu; Xaiowei Xu; Xiangfan Yin; Nancy R Zhang; Michael A Davies; Meenhard Herlyn; Katherine L Nathanson
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

Review 8.  Emerging strategies to treat rare and intractable subtypes of melanoma.

Authors:  Gretchen M Alicea; Vito W Rebecca
Journal:  Pigment Cell Melanoma Res       Date:  2020-04-24       Impact factor: 4.693

9.  Polyunsaturated Fatty Acids from Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis.

Authors:  Yongkang Zou; Andrea Watters; Nan Cheng; Caroline E Perry; Ke Xu; Gretchen M Alicea; Joshua L D Parris; Ezra Baraban; Pulak Ray; Anupma Nayak; Xiaowei Xu; Meenhard Herlyn; Maureen E Murphy; Ashani T Weeraratna; Zachary T Schug; Qing Chen
Journal:  Cancer Discov       Date:  2019-10-02       Impact factor: 39.397

Review 10.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.